Bayer closes acquisition of customer treatment business of Merck & harmfull effects.

Bayer closes acquisition of customer treatment business of Merck & Co harmfull effects ., Inc., USA, for USD 14.2 billion Bayer offers completed the acquisition of the buyer treatment business of the U.S. Pharmaceuticals group Merck & Co., Inc., Whitehouse Station, NJ. On October 1 The transaction shut, 2014, pursuing receipt of needed antitrust approvals. ‘This acquisition is certainly a milestone for Bayer and we plan to continue the growth of our appealing over-the-counter business both through organic development and bolt-on acquisitions,’ described Bayer CEO Dr.